State of New Jersey Common Pension Fund D Has $1.58 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

State of New Jersey Common Pension Fund D decreased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,839 shares of the company’s stock after selling 1,953 shares during the period. State of New Jersey Common Pension Fund D owned 0.06% of IDEAYA Biosciences worth $1,579,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in IDEAYA Biosciences during the 1st quarter valued at $101,000. ProShare Advisors LLC grew its stake in shares of IDEAYA Biosciences by 21.1% during the 1st quarter. ProShare Advisors LLC now owns 17,047 shares of the company’s stock worth $748,000 after acquiring an additional 2,966 shares during the period. Orion Portfolio Solutions LLC bought a new stake in shares of IDEAYA Biosciences in the first quarter valued at approximately $1,431,000. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock valued at $182,355,000 after acquiring an additional 679,985 shares during the period. Finally, Covestor Ltd lifted its holdings in IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after purchasing an additional 1,107 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IDYA shares. UBS Group started coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research note on Monday, November 4th. Stephens initiated coverage on IDEAYA Biosciences in a research note on Monday. They issued an “overweight” rating and a $51.00 target price on the stock. Citigroup reduced their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Finally, Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.67.

IDEAYA Biosciences Trading Down 1.7 %

Shares of NASDAQ IDYA opened at $26.19 on Tuesday. IDEAYA Biosciences, Inc. has a 12 month low of $25.62 and a 12 month high of $47.74. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -11.24 and a beta of 0.86. The company has a 50 day simple moving average of $31.22 and a two-hundred day simple moving average of $36.19.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period last year, the firm earned ($0.46) EPS. Analysts forecast that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.